Rule2024-15136
Advisory Committee; Allergenic Products Advisory Committee; Termination; Removal From List of Standing Committees
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 10, 2024
Effective
July 10, 2024
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is announcing the termination of the Allergenic Products Advisory Committee, Center for Biologics Evaluation and Research. This document announces the reasons for termination and removes the Allergenic Products Advisory Committee from the Agency's list of standing advisory committees.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 132 (Wednesday, July 10, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 132 (Wednesday, July 10, 2024)]
[Rules and Regulations]
[Pages 56662-56663]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-15136]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 14
[Docket No. FDA-2024-N-3008]
Advisory Committee; Allergenic Products Advisory Committee;
Termination; Removal From List of Standing Committees
AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the termination of the Allergenic Products Advisory Committee, Center
for Biologics Evaluation and Research. This document announces the
reasons for termination and removes the Allergenic Products Advisory
Committee from the Agency's list of standing advisory committees.
DATES: This rule is effective July 10, 2024.
FOR FURTHER INFORMATION CONTACT: Prabhakara Atreya, Division of
Scientific Advisors and Consultants, Center for Biologics Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 71, Silver Spring, MD 20993-0002, 240-506-4946,
<a href="/cdn-cgi/l/email-protection#f2a28093909a9399938093dcb38680978b93b2949693dc9a9a81dc959d84"><span class="__cf_email__" data-cfemail="62321003000a03090310034c231610071b03220406034c0a0a114c050d14">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The Allergenic Products Advisory Committee
(the Committee) was established on July 9, 1984 (49 FR 30688). The
Committee advises the Commissioner of Food and Drugs (Commissioner) or
designee in discharging responsibilities as they relate to helping to
ensure safe and effective drugs for human use and as required, any
other product for which FDA has regulatory responsibility.
The Committee reviews and evaluates data concerning the safety,
effectiveness, and adequacy of labeling of marketed and investigational
allergenic biological products or materials that are administered to
humans for the diagnosis, prevention, or treatment of allergies and
allergic disease, and makes appropriate recommendations to the
Commissioner of its findings regarding the affirmation or revocation of
biological product licenses, on the safety, effectiveness, and labeling
of the products, on clinical and laboratory studies of such products,
on amendments or revisions to regulations governing the manufacture,
testing, and licensing of allergenic biological products, and on the
quality and relevance of FDA's research programs that provide the
scientific support for regulating these agents.
Over the past several years, the Committee has met infrequently. As
such, the effort and expense of maintaining the Committee can no longer
be justified. The Committee will be terminated on July 9, 2024. The
responsibilities of this Committee will be integrated into the Vaccines
and Related Biological Products Advisory Committee (VRBPAC) charter
ensuring that FDA has a mechanism to seek independent expert input on
allergenic biological products. Specifically, the VRBPAC charter will
be revised such that VRBPAC will be available to provide advice and
recommendations to the Commissioner on allergenic biological products
or materials for humans for the diagnosis, prevention, or treatment of
allergies and allergic disease, as appropriate.
Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e),
the Agency finds good cause to dispense with notice and public comment
procedures and to proceed to an immediate effective date on this rule.
Notice and public comment and a delayed effective date are
unnecessary because the Committee is not being adequately used, and
termination of the committee is effective on July 9, 2024, in
accordance with 21 CFR 14.55. This final rule merely removes the name
of the Allergenic Products Advisory Committee from the list of standing
advisory committees in Sec. 14.100 (21 CFR 14.100).
Therefore, the Agency is amending Sec. 14.100(b) as set forth in
the regulatory text of the document.
List of Subjects in 21 CFR Part 14
Administrative practice and procedure, Advisory committees, Color
additives, Drugs, Radiation protection.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
14 is amended as follows:
PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE
0
1. The authority citation for part 14 continues to read as follows:
Authority: 5 U.S.C. 1001 et seq.; 15 U.S.C. 1451-1461; 21
U.S.C. 41-50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C.
2112; 42 U.S.C. 201, 262, 263b, 264, 284m, 284m-1; Pub. L. 107-109,
115 Stat. 1419.
[[Page 56663]]
Sec. 14.100 [Amended]
0
2. Amend Sec. 14.100 by removing paragraph (b)(1) and redesignating
paragraphs (b)(2) through (4) as paragraphs (b)(1) through (3).
Dated: July 5, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-15136 Filed 7-9-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 10, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.